These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32095510)

  • 1. The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients.
    Kukla A; Hill J; Merzkani M; Bentall A; Lorenz EC; Park WD; D'Costa M; Kudva YC; Stegall MD; Shah P
    Transplant Direct; 2020 Feb; 6(2):e524. PubMed ID: 32095510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modern glucose-lowering drugs in liver transplant recipients: improvement in weight, glycemic control, and potentially allograft steatosis.
    Atthota S; Joyal K; Cote M; Scalzo R; Singh R; Consul N; Kilcoyne A; Bethea ED; Dageforde LA
    Front Transplant; 2023; 2():1223169. PubMed ID: 38993868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GLP-1 physiology informs the pharmacotherapy of obesity.
    Drucker DJ
    Mol Metab; 2022 Mar; 57():101351. PubMed ID: 34626851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation.
    Gruessner RW; Burke GW; Stratta R; Sollinger H; Benedetti E; Marsh C; Stock P; Boudreaux JP; Martin M; Drangstveit MB; Sutherland DE; Gruessner A
    Transplantation; 1996 Jan; 61(2):261-73. PubMed ID: 8600635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Study of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Diabetes After Transplantation.
    Thangavelu T; Lyden E; Shivaswamy V
    Diabetes Ther; 2020 Apr; 11(4):987-994. PubMed ID: 32072430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target Mendelian randomization and clinical trials.
    Sun Y; Liu Y; Dian Y; Zeng F; Deng G; Lei S
    Int J Surg; 2024 May; ():. PubMed ID: 38701500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for preventing thrombosis in solid organ transplant recipients.
    Surianarayanan V; Hoather TJ; Tingle SJ; Thompson ER; Hanley J; Wilson CH
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD011557. PubMed ID: 33720396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group.
    Woodle ES; Thistlethwaite JR; Gordon JH; Laskow D; Deierhoi MH; Burdick J; Pirsch JD; Sollinger H; Vincenti F; Burrows L; Schwartz B; Danovitch GM; Wilkinson AH; Shaffer D; Simpson MA; Freeman RB; Rohrer RJ; Mendez R; Aswad S; Munn SR; Wiesner RH; Delmonico FL; Neylan J; Whelchel J
    Transplantation; 1996 Sep; 62(5):594-9. PubMed ID: 8830821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Mycophenolate Mofetil Dose Reduction on Allograft Outcomes in Kidney Transplant Recipients on Tacrolimus-Based Regimens: A Systematic Review.
    Su VCh; Greanya ED; Ensom MH
    Ann Pharmacother; 2011 Feb; 45(2):248-57. PubMed ID: 21304036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients.
    Peddi VR; Bryant M; Roy-Chaudhury P; Woodle ES; First MR
    Transplantation; 2002 May; 73(9):1514-8. PubMed ID: 12023634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of chronic allograft rejection on plasma regulators of fibrinolysis.
    Perkowska A; Elhasade A; Durlik M; Placha G; Gałazka Z; Lao M; Gaciong Z
    Ann Transplant; 2002; 7(1):44-51. PubMed ID: 12221903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of cardiovascular, renal and safety outcomes of second-line antidiabetic drugs use in people with type 2 diabetes: A systematic review and network meta-analysis of randomised controlled trials.
    Sim R; Chong CW; Loganadan NK; Fong AYY; Navaravong L; Hussein Z; Khunti K; Lee SWH
    Diabet Med; 2022 Mar; 39(3):e14780. PubMed ID: 34962662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thymoglobulin for induction or rejection therapy in pancreas allograft recipients: a single centre experience.
    Trofe J; Stratta RJ; Egidi MF; Lo A; Gaber LW; Shokouh-Amiri MH; Grewal HP; Honaker M; Hardinger K; Alloway RR; Gaber AO
    Clin Transplant; 2002; 16 Suppl 7():34-44. PubMed ID: 12372042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
    Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients.
    Scharp DW; Lacy PE; Santiago JV; McCullough CS; Weide LG; Boyle PJ; Falqui L; Marchetti P; Ricordi C; Gingerich RL
    Transplantation; 1991 Jan; 51(1):76-85. PubMed ID: 1987709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases.
    Wang J; Kim CH
    Endocr Res; 2022 Feb; 47(1):18-25. PubMed ID: 34459679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience.
    Piazzolla G; Vozza A; Volpe S; Bergamasco A; Triggiani V; Lisco G; Falconieri M; Tortorella C; Solfrizzi V; Sabbà C
    Open Med (Wars); 2022; 17(1):1203-1215. PubMed ID: 35859794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.